METHODS
• New drugs approved from January 2011 through December 2015 were identified using the Drugs@FDA database.
• Data were extracted from publications related to the review of PRO labeling between 2006 and 2010.
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• Approved product labeling and medical review sections from FDA drug approval packages were reviewed to identify indication and the primary endpoint of confirmatory studies.
• ICD-10 codes were used to classify disease, and the primary endpoints were classified based on the type of outcome assessment (e.g., PRO, clinician-reported outcome [ClinRO], biomarker).
• Data were recorded in Microsoft Excel; frequency of measured characteristics was analyzed descriptively.
RESULTS

Overall NME Approvals
• A total of 182 NMEs were approved from 2011-2015; of these, 30 (16.5%) received PRO labeling.
• From 2011 through 2015, 58.8% of the NMEs approved were products for cancer; infectious and parasitic diseases; and endocrine, nutritional, and metabolic diseases (Table 1 ).
• NMEs approved for these three major categories of diseases also showed largest increases in approvals from 2006-2010 to 2011-2015. Table 1 shows that NME approvals related to cancer; infectious and parasitic diseases; and endocrine, nutritional, and metabolic diseases increased by 137.8%. The largest increase (177.8%) was in approvals of cancer drugs (Table 1 ).
• 
PRO Labeling
• Table 2 shows that over the entire review period of 10 years (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) , PRO labeling for approved NMEs for the three major disease categories was scarce (n = 7; 12.1%).
• Excluding the NME approvals related to the three major disease categories that showed the largest increases in approvals between period 2006-2010 and 2011-2015, the percentage of PRO labeling was comparable for the period 2006-2010 (38.0%) and 2011-2015 and 32.0% (Table 3) .
DISCUSSION
• Overall, the percentage of PRO labeling of NMEs decreased from 24.1% for the period 2006-2010 to 16.5% for the period 2011-2015.
• This reduction was likely due to the increase in drug approvals in three disease categories in which PROs traditionally do not play a role in the assessment of treatment benefit (cancer; infectious and parasitic diseases; and endocrine, nutritional, and metabolic diseases). PRO labeling for these three categories is difficult for the following reasons:
-Cancer-development of cancer drugs relies largely on survivalrelated endpoints and single-arm or open-label study designs that may not be considered suitable for the interpretation of PRO data.⁵ -Infectious and parasitic diseases-approval of drugs for these diseases mostly relies on some measure of pathogen activity (e.g., sustained virology response) and traditionally does not rely on PROs for assessing treatment benefit.
-Nutritional and metabolic diseases-these are mostly asymptomatic (e.g., familial hypercholesterolemia or diabetes) and therefore do not traditionally rely on PROs for assessing treatment benefit.
• When these three major disease categories of NME approvals are excluded, the percentage of NMEs with PRO labeling for the • PRO labeling based only on secondary endpoints for 7 of the 30 products in the last 5 years (2011-2015) is perhaps indicative of sponsors' reluctance to allocate sufficient resources to secondary endpoints to meet the required regulatory standard.
CONCLUSIONS
• PRO claims continue to be approved by the FDA. While the overall percentage of products with PRO labels appears to have decreased from 2011-2015, this is due in large part to an increase in the number of products approved for cancer; infectious and parasitic diseases; and endocrine, nutritional, and metabolic diseases. Table 2 
Endpoint Status
• The majority of PRO labeling (76.7%) during 2011-2015 was based on primary endpoints. PRO labeling for seven products was based only on secondary endpoints; for six of these products, the primary endpoints were biomarkers (Table 4) . 
